Adam Dubow - Bristol Myer President

BMYMP
 Stock
  

USD 1,101  0.00  0.00%   

  President
Mr. Adam Dubow is Senior Vice President, Chief Compliance Officer and Ethics Officer of the company. From 2013 to 2015 Vice President and Assistant General Counsel, China, Japan and Intercon Region and EMAC Region. 2015 to 2018 Vice President and Associate General Counsel, Research and Development. 2018 to present Senior Vice President, Chief Compliance and Ethics Officer.
Age: 51  President Since 2018      
212-546-4000  http://www.bms.com

Adam Dubow Latest Insider Activity

Tracking and analyzing the buying and selling activities of Adam Dubow against Bristol Myer otc stock is an integral part of due diligence when investing in Bristol Myer. Adam Dubow insider activity provides valuable insight into whether Bristol Myer is net buyers or sellers over its current business cycle. Note, Bristol Myer insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bristol Myer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Bristol Myer Management Efficiency

Bristol Myer Squi has return on total asset (ROA) of 10.68 % which means that it generated profit of $10.68 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 2.97 %, meaning that it generated $2.97 on every $100 dollars invested by stockholders. Bristol Myer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 7.39 B in total debt with debt to equity ratio (D/E) of 59.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bristol Myer Squi has a current ratio of 1.37, which is within standard range for the sector. Debt can assist Bristol Myer until it has trouble settling it off, either with new capital or with free cash flow. So, Bristol Myer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bristol Myer Squi sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bristol to invest in growth at high rates of return. When we think about Bristol Myer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

PRESIDENT Since

Robert HarrisonTarget Corp
2015
Masaaki KonoMIZUHO FINANCIAL GROUP
2013
Stephanie LundquistTarget Corp
2019
Jason GoldbergerTarget Corp
2016
Jacqueline RiceTarget Corp
2014
Timothy RoseCostco Wholesale
2012
Lorna FergusonNio Inc ADR
1998
Johny SroujiApple Inc
2015
Minsok PakTarget Corp
2017
Michael McNamaraTarget Corp
2019
Laysha WardTarget Corp
2017
Xin ZhouNio Inc ADR
2015
Craig FederighiApple Inc
2012
Joel SlagerNio Inc ADR
2013
Durward SewellApple Inc
2009
Bruce SewellApple Inc
2009
Philip SchillerApple Inc
2002
Hsien ChengNio Inc ADR
N/A
Michael FiddelkeTarget Corp
2019
Satoshi MiyazakiMIZUHO FINANCIAL GROUP
2016
Douglas SchuttCostco Wholesale
2010
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people. Bristol Myer Squi [BMYMP] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Bristol Myer Squi Leadership Team

Elected by the shareholders, the Bristol Myer's board of directors comprises two types of representatives: Bristol Myer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myer's management team and ensure that shareholders' interests are well served. Bristol Myer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myer's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, CFO, Executive Vice President
Gerald Storch, Independent Director
Louis Schmukler, President - Global Manufacturing and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
John Elicker, Senior Vice President - Public Affairs and Investor Relations
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President Controller
Giovanni Caforio, COO, Director
Vicki Sato, Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Joseph Caldarella, Senior Vice President Corporate Controller
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, CEO, Director
Thomas Lynch, Independent Director
Dinesh Paliwal, Independent Director
Lewis Campbell, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Senior Vice President - Global Human Resources
Sandra Leung, General Counsel, Corporate Secretary
Paul Autenried, Senior Vice President - Enterprise Services, CIO
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President Head - Business Development
Peter Arduini, Independent Director

Bristol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Bristol Myer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Bristol Myer Investors Sentiment

The influence of Bristol Myer's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bristol. The overall investor sentiment generally increases the direction of a otc movement in a one-year investment horizon. However, the impact of investor sentiment on the entire otc markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Bristol Myer's public news can be used to forecast risks associated with investment in Bristol. The trend in average sentiment can be used to explain how an investor holding Bristol can time the market purely based on public headlines and social activities around Bristol Myer Squi. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Bristol Myer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bristol Myer's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bristol Myer's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bristol Myer.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol Myer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol Myer's short interest history, or implied volatility extrapolated from Bristol Myer options trading.

Pair Trading with Bristol Myer

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myer will appreciate offsetting losses from the drop in the long position's value.

Moving against Bristol Myer

0.8AAPLApple Inc Fiscal Year End 27th of October 2022 PairCorr
0.67EPACActuant Corp Fiscal Year End 5th of October 2022 PairCorr
0.62UECUranium Energy Normal TradingPairCorr
0.61CCitigroup Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to Bristol Myer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myer Squi to buy it.
The correlation of Bristol Myer is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myer Squi moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Bristol Myer Squi information on this page should be used as a complementary analysis to other Bristol Myer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Bristol OTC Stock analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1804.8 B
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.